Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

NCT05594992 is registered in ClinicalTrials.gov with JCR Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05594992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05594992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects
Lead sponsor
JCR Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
February 22, 2023
Completion date
February 28, 2028
Enrollment
80 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis ii